The Future of Vaccines
|
|
Alan R. Hinman, MD, MPH, is Senior Public Health Scientist at The Task Force for Child Survival and Development at Emory University and The Carter Center. He has worked in public health at the state, national, and international levels, primarily with CDC, where he directed the Immunization Division (1988-1988) and the National Center for Prevention Services (1988-2005). |
|
Paul A. Offit, MD, is Chief of the Division of Infectious Diseases and Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia. He is also the Maurice R. Hilleman Professor of Vaccinology and Professor of Pediatrics at the University of Pennsylvania School of Medicine. He is co-inventor of the rotavirus vaccine, RotaTeq, recently recommended for universal use in infants by the CDC. |
|
Stanley A. Plotkin, MD, is Emeritus Professor at the University of Pennsylvania and Executive Advisor to Sanofi Pasteur. He developed the rubella vaccine now in standard use throughout the world, co-developed the newly licensed pentavalent rotavirus vaccine, and has worked on the development of other vaccines including those against polio, rabies, varicella, and cytomegalovirus. |
|
Thomas M. Vernon, MD, was Vice President for Policy, Public Health and Medical Affairs at Merck & Co. until 2004. Previously, he was State Epidemiologist and Executive Director of the Colorado Department of Health and Director of Health and Human Services at the Pew Charitable Trusts. |
| Moderator: | |
|
Arthur L. Caplan, PhD, is the Emmanuel and Robert Hart Professor of Bioethics, Chair of the Department of Medical Ethics, and Director of the Center for Bioethics at the University of Pennsylvanian. He is the author of numerous books and articles on bioethics and is a frequent guest and commentator on various media outlets. |
About USP
University of the Sciences in Philadelphia (USP)
University of the Sciences in Philadelphia is a private, coeducational institution dedicated to education, research, and service. Comprising five colleges, including its new Mayes College of Healthcare Business and Policy, USP specializes in educating its 2,800 students for rewarding careers through its undergraduate, graduate, and doctoral degree programs in pharmacy, health and related sciences, and healthcare business and health policy. Founded in 1821 as the nation’s first college of pharmacy, it is where the founders of six of the top pharmaceutical companies in the world launched their futures.
Mayes College of Healthcare Business and Policy
The Mayes College of Healthcare Business and Policy at USP prepares undergraduate and graduate students to make an impact on the critical healthcare needs of society, and to compete in the evolving healthcare arena ... where business, policy, and public needs intersect. Degree programs include an MBA in pharmaceutical business, an MS and PhD in health policy, master in public health (MPH), MS in biomedical writing, or BS in pharmaceutical marketing and management. Students in Mayes College benefit not only from USP’s alumni networks but also from the region’s rich life sciences economy, including the extensive network of healthcare, regulatory, pharmaceutical, and biotech industries.
Department of Health Policy and Public Health
The Department of Health Policy and Public Health at USP’s Mayes College of Healthcare Business and Policy offers MPH, MS, and PhD degrees, with curricula focusing on professional analysis and scholarly research in health policy. Ongoing research covers a broad range of topics affecting national health policy debates, including healthcare regulation, urban health, medical interventions in the developing world, geriatric health, pharmaceutical industry structure, and insurance benefit design. More information on the Department’s faculty, research, and community activities is available at www.healthpolicy.usp.edu.
Registration: To register online, please go to www.usp.edu/symposium/register.aspx or call 1.866.431.0845. Please respond by Thursday, May 1, 2008